Important Information
Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
DISCLAIMER – IMPORTANT
Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada or Japan, or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction. We apologize for any inconvenience this may cause. Click here to return to the homepage.
Important Information
Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
The information contained in this section of the website of Asker Healthcare Group AB (the “Company”) (a) is only intended for, and may only be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Canada, or Japan, and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regulations of such jurisdiction and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any securities of the Company in the United States, Australia, Canada, Japan, or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
The securities of the Company referred to in this section of the Company’s website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States and may not be offered or sold within the United States unless the Securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
The Securities have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan, or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Canada, Japan or any other jurisdiction in which it would be unlawful or would require registration or other measures.
In the United Kingdom, the information contained in this section of the Company’s website is only being distributed to and is only directed at “qualified investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 who are (i)investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) and (ii) above together being referred to as “relevant persons”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the information contained in this section of the Company’s website.
In any EEA Member State, other than Sweden, where Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “Prospectus Regulation”) is applicable, the information contained in this section of the Company’s website are only addressed to and are only directed at qualified investors within the meaning of the Prospectus Regulation.
Access to the information contained in this section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information. All persons residing outside of Sweden who wish to have access to the information contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the Company’s website, or require registration or approval for any acquisition of Securities by them. No such registration or approval has been or will be obtained outside of Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
I therefore certify that:
- I am resident and physically present in a country outside the United States, Australia, Canada and Japan;
- I am authorised to access the information contained in this section of the Company’s website without being subject to any legal restriction and without any further action required by the Company;
- I will not transmit or otherwise send any information contained in this website to publications with a general circulation in the United States; and
- I have read, understand and agree to comply with all of the restrictions set forth above.
DISCLAIMER – IMPORTANT
Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada or Japan, or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction. We apologize for any inconvenience this may cause. Click here to return to the homepage.
Exercise of the overallotment option in Asker and end of the stabilisation period in advance
Carnegie Investment Bank AB (publ) (”Carnegie”), Citigroup Global Markets Europe AG (”Citigroup”) and Nordea Bank Abp, filial i Sverige (“Nordea”, and together with Carnegie and Citigroup, the “Joint Global Coordinators”) have today notified Asker Healthcare Group AB (publ) (“Asker” or the “Company”), Nalka Invest AB1 (“Nalka”) and Ilmarinen Mutual Pension Insurance Company (“Ilmarinen”) that the overallotment option has been exercised in full. Nordea, as stabilisation manager on behalf of the Joint Global Coordinators, has notified that the stabilisation period has now ended in advance. No price stabilisation measures have been or will be carried out.
In connection with the offering and listing of Asker’s shares on Nasdaq Stockholm on 27 March 2025 (the “Offering”), the shareholders Nalka and Ilmarinen issued an option entitling the Joint Global Coordinators to request that up to an additional 19,042,965 shares, corresponding to 15 percent of the total number of shares in the Offering, are acquired to cover any overallotment in the Offering.
No price stabilisation measures have been carried out since the listing on 27 March 2025, and in light of the Company’s share price performance, the Joint Global Coordinators have decided to fully exercise the overallotment option and Nordea, as stabilisation manager on behalf of the Joint Global Coordinators, has notified that the stabilisation period has now ended in advance.
For further information, please contact:
Emma Rheborg, Head of Communications
Tel: +46733136217
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact persons set out above, at 19:15 CEST on 7 April 2025.
Asker Healthcare Group is a partner to caregivers and patients across Europe providing medical products and solutions. We build and acquire leading companies that together support the healthcare system to improve patient outcomes, reduce total cost of care and ensure a fair and sustainable value chain. We are a European healthcare group that combines the entrepreneurial drive of strong local companies, with the abilities and collected knowledge of a large group – driving progress in the healthcare sector. The group has more than 4,000 employees in 17 countries.
IMPORTANT INFORMATION
This announcement is not, and does not form part of, an offer to sell or buy any securities. This announcement is not being made, and may not be distributed in or sent to, the United States of America, Australia, Canada, or Japan, or any other jurisdiction where such distribution would be unlawful or require registration or any other measures.
The offering of the securities referred to in this announcement has been made by means of a prospectus (the “Prospectus”). This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “Prospectus Regulation”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned Prospectus.
This announcement and the information contained herein are not for distribution in or into the United States of America. This announcement does not constitute an offer to sell securities in the United States of America. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States of America without registration or an exemption from registration under the Securities Act and in accordance with applicable securities laws of the states of the United States of America. No public offering of securities is being made in the United States of America.
This announcement is only addressed to and are only directed at persons in any member state of the EEA, with the exception of Sweden, Denmark, Norway, Finland and the United Kingdom (each a “Relevant State”) who are “Qualified Investors” within the meaning of Article 2(e) of the Prospectus Regulation or the Prospectus Regulation made part of United Kingdom law by the European Union (Withdrawal) Act 2018, as applicable.
This announcement does not constitute an offer of securities to the public in the United Kingdom. No prospectus has been or will be registered in the United Kingdom in respect of the securities. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, qualified investors (as defined in the Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018) and who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This announcement must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so.
This announcement may contain certain forward-looking statements. Such statements include statements regarding the Company’s business strategy, financial condition, profitability, market data and other statements that are not historical facts and include expressions such as “believes”, “considers”, “estimates”, “expects”, “anticipates”, “assumes”, “predicts”, “intends”, “may”, “continues”, “should”, “aims”, “forecasts”, “guides” or similar expressions. The forward-looking statements in this announcement are based on various estimates and assumptions, many of which are based on additional assumptions. Although the Company believes that these assumptions were reasonable when made, such forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that are difficult or impossible to predict and are beyond the Company's control. Such risks, uncertainties and material factors could cause actual results to differ materially from those expressed or implied in this announcement by the forward-looking statements. The information, beliefs and forward-looking statements contained in this announcement speak only as of the date of this announcement and are subject to change without notice.
----------------------------------------------------
1. Nalka Invest AB holds shares in the Company through Strukturfonden HC15 AB (corporate registration number 556898-7928) and Strukturfonden HC15 II AB (corporate registration number 559342-6280).